Mersana Therapeutics, Inc.
MRSN
$28.59
$0.240.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.08% | 29.34% | 45.10% | 59.69% | 62.13% |
| Total Depreciation and Amortization | -35.16% | -17.35% | -6.17% | 7.32% | 23.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.75% | -13.18% | -18.42% | -20.33% | -25.07% |
| Change in Net Operating Assets | 52.71% | 53.04% | 62.58% | -63.82% | -159.23% |
| Cash from Operations | 21.76% | 39.83% | 54.21% | 51.24% | 49.48% |
| Capital Expenditure | 100.00% | 100.00% | 100.00% | 93.91% | 79.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 530.24% | 82.21% | 134.49% | -90.52% | -131.47% |
| Cash from Investing | 522.30% | 86.08% | 141.58% | -90.46% | -133.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12,900.00% | -3,353.50% | -1,923.66% | -751.15% | 22.99% |
| Issuance of Common Stock | -95.89% | -95.89% | -99.46% | -93.36% | -95.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -527.58% | -237.23% | -106.17% | -95.68% | -95.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 79.07% | 125.78% | 156.89% | -246.27% | -4,980.28% |